Background: Cardioprotection by volatile anesthetic-induced preconditioning is known to involve intracellular signaling pathways. Recent studies have shown that protein kinase C (PKC) plays an important role in anesthetic-induced preconditioning. In this study, the effects of the activation of specific isozymes of PKC, specifically PKC-⑀ and -␦, on the modulation of the sarcolemmal adenosine triphosphate-sensitive potassium (sarcK ATP ) channel by isoflurane were investigated.
VOLATILE anesthetics have been reported to provide the myocardium with tolerance against a subsequent ischemic attack in various species, [1] [2] [3] [4] including hu-mans. 5 This cardioprotective action is termed anesthetic-induced preconditioning (APC) and is as effective as ischemic preconditioning (IPC). Although the cellular and molecular mechanisms underlying APC and IPC have yet to be fully elucidated, strong evidence supports a significant role for the adenosine triphosphate (ATP)sensitive potassium (K ATP ) channels. 6 -8 Because these channels act as metabolic sensors, they provide an attractive target underlying APC and IPC. Earlier studies have focused on the potential role of the sarcolemmal K ATP (sarcK ATP ) channels. Recently, the K ATP channel was also identified on the inner membrane of the mitochondria (mitoK ATP channel), 9 but its molecular identity remains elusive. Recent studies have provided accumulating evidence toward a more significant role for the mitoK ATP channel, rather than the sarcK ATP channel, in both APC and IPC. 10, 11 However, the contribution of the sarcK ATP channel cannot be discounted because in some cases, both the mitoK ATP and sarcK ATP channels may underlie the cardioprotective effect. 12, 13 Moreover, Suzuki et al. 14 demonstrated that diazoxide, a specific mitoK ATP channel opener, did not afford cardioprotection after ischemia in a knockout mice deficient with the gene encoding Kir6.2, the pore-forming region of the sarcK ATP channel.
It seems likely that the opening of mitoK ATP channel acts as a trigger for cardioprotection by IPC 15 and APC. 11 Opening of the mitoK ATP channel is thought to activate signaling cascades that include the translocation of specific protein kinase C (PKC) isozymes. In particular, the PKC-⑀ and PKC-␦ isozymes have been reported to be critical components underlying cardiac preconditioning. PKC-⑀ was reported to have a beneficial action, 16 -18 whereas the inhibition of the PKC-␦ isoform did not block the cardioprotective effect of IPC. 17, 18 APC by sevoflurane seemed to involve only PKC-⑀ but not PKC-␦ in a guinea pig model. 19 However, translocation of PKC-␦ to the mitochondria may play a significant role in APC and IPC, which was demonstrated in rat hearts. 20 Although activation of the mitoK ATP channel is likely to be a critical event during the initial phase of cardiac preconditioning, the subsequent changes in the signaling cascade can potentially modulate the sarcK ATP channel. In particular, the sarcK ATP channel may play a pivotal role during ischemia and reperfusion, downstream from the events associated with mitoK ATP channel opening. 21 We have previously reported that PKC activation by a phorbol ester can facilitate opening of the sarcK ATP channel by isoflurane. 22 In the current study, we investigated whether the PKC-⑀ and PKC-␦ isozymes modulated the action of isoflurane on the sarcK ATP channel.
Materials and Methods

Cell Isolation
All experiments were approved by the Animal Care and Use Committee of the Medical College of Wisconsin (Milwaukee, Wisconsin). Single cardiac ventricular myocytes were enzymatically isolated from adult guinea pigs (either sex) weighing 150 -300 g as previously described, 23 using a modified isolation method of Mitra and Morad. 24 Briefly, the guinea pigs were intraperitoneally injected with heparin (1,000 U/ml) and anesthetized with pentobarbital sodium (250 mg/kg). After thoracotomy, the hearts were quickly removed and mounted on a Langendorff apparatus. They were perfused retrogradely through the aorta with warm (37°C) oxygenated Joklik medium (Sigma-Aldrich, St. Louis, MO) containing 2.5 U/ml heparin. After blood had been washed out, the hearts were perfused for 8 -12 min by an enzyme solution containing Joklik medium, 0.3 mg/ml collagenase type II (Gibco BRL; Invitrogen, Grand Island, NY), 0.1 mg/ml protease type XIV (Sigma-Aldrich), and 0.1 mg/ml bovine serum albumin (Serelogicals Corporation, Kankakee, IL), at pH 7.23. The ventricles were then minced and incubated for an additional 3-10 min in the enzyme solution. Isolated myocytes were washed and stored in a Tyrode solution at room temperature (22°C) and used for experiments within 12 h of the isolation procedure.
Solutions
The modified Tyrode solution contained 132 mM NaCl, 4.8 mM KCl, 1.2 mM MgCl 2 , 1 mM CaCl 2 , 10 mM HEPES, and 5 mM glucose, at pH 7.3 adjusted with NaOH. The intracellular pipette solution contained 60 mM L-glutamic acid, 50 mM KCl, 10 mM HEPES, 1 mM MgCl 2 , 11 mM EGTA, 1 mM CaCl 2 , and 0.5 mM K 2 ATP, at pH 7.4 adjusted with KOH. The external bath solution contained 132 mM N-methyl-D-glucamine, 2 mM MgCl 2 , 5 mM KCl, 1 mM CaCl 2 , and 10 mM HEPES, at pH 7.4 adjusted with HCl. Nisoldipine, a gift from Miles-Pentex (West Haven, CT), was added to the external solution at a concentration of 200 nM to block the L-type calcium channels. The 1-mM stock solution of nisoldipine was made in polyethylene glycol. The 10-mM stock solution of pinacidil (Lilly Laboratories, Indianapolis, IN), a K ATP channel opener, was prepared in dimethyl sulfoxide. The 1-mM stock solution of glibenclamide (Sigma-Aldrich), a K ATP channel blocker, was also prepared in dimethyl sulfoxide. 5-Hydroxydecanoate (5-HD; Sigma-Aldrich), a specific blocker of the mitoK ATP channels, was prepared as a 10-mM stock solution in water.
To investigate the effects of PKC-⑀ and PKC-␦ on the sarcK ATP channel, membrane permeable peptides (conjugated to the antennapedia carrier) of the PKC-⑀ and PKC-␦ translocation activators and inhibitors, including a scrambled PKC-⑀ peptide, were used. These peptides were obtained from Daria Mochly-Rosen, Ph.D. (Professor and Chair, Department of Molecular Pharmacology, Stanford University School of Medicine, Stanford, California). 25 The 1-M stock solutions of these peptides were prepared in the external bath solution, stored at Ϫ20°C, and thawed before use. The specificity of each PKC peptide is high. The peptide activator mimics the isozyme-specific receptors for activated C-kinase (RACK) binding site and causes the conformational change of a specific PKC isoform, allowing it to translocate to its corresponding RACK. The peptide inhibitor inhibits the translocation of an activated PKC isozyme by blocking the binding site of its corresponding RACK.
Isoflurane (Abbott Laboratories, North Chicago, IL) was dispersed in the external bath solution, kept in glass-syringe reservoirs to ensure a constant concentration, and delivered to the recording chamber via syringe pumps. At the end of each experiment, solution samples were collected, and the concentrations of isoflurane in the recording chamber were measured using gas chromatography (Shimadzu, Kyoto, Japan), as previously reported. 23 The concentration of isoflurane used in this study was 0.88 Ϯ 0.05 mM, which is equivalent to 1.86 vol% (1.55 minimum alveolar concentration [MAC]) at 22°C.
Electrophysiologic Recordings and Data Analysis
Sarcolemmal K ATP channel current (I KATP ) was measured in the whole cell configuration of the patch clamp technique, using an EPC-7 patch clamp amplifier (List, Darmstadt-Eberstadt, Germany) and Digidata 1322A interface (Axon Instruments, Foster City, CA). pClamp8 software (Axon Instruments) was used for data acquisition and analysis. Patch pipettes with resistances ranging from 2 to 3 M⍀ were pulled from borosilicate glass (Garner Glass, Claremont, CA) using a programmable micropipette puller (Sachs-Flaminh PC-84; Sutter Instruments, Novato, CA). Pipette tips were heat polished using a microforge MF-83 (Narishige, Tokyo, Japan). The cells suspended in Tyrode solution were placed in the recording chamber on the stage of an inverted microscope (Diaphot 300; Nikon, Tokyo, Japan). Only quiescent, rod-shaped cells with distinct striations were selected for experiments.
After a gigaohm seal was formed and the whole cell configuration was established by membrane rupture, the series resistance was adjusted to give the fastest possible capacitance transient without causing ringing. Whole cell I KATP was monitored during a 100-ms depolarizing voltage step to 0 mV applied every 15 s from a holding potential of Ϫ40 mV. Current signal was sampled at 10 kHz and low-pass filtered at a cutoff frequency of 3 kHz. Current amplitude was measured at the end of the voltage step. To allow for comparisons among cells, currents were normalized to cell capacitance and reported as current density (pA/pF).
Immunohistochemistry
Left ventricular tissue samples of guinea pigs hearts obtained from the control and the anesthetic preconditioned groups were snap-frozen in liquid nitrogen and stored at Ϫ70°C. Cryosections (10 m) of the tissue were mounted on positively charged microscope slides. Sections were fixed for 10 min in 100% acetone at Ϫ20°C and rinsed with phosphate-buffered saline (PBS). Subsequently, the sections were incubated with 1:50 dilutions of rabbit polyclonal primary antibodies in PBS against PKC-⑀ and PKC-␦ (Santa Cruz Biotechnology, Santa Cruz, CA) for 30 min at 37°C. The slides were then washed three times for 5 min in PBS, and the sections were incubated with a 1:1,000 dilution of anti-rabbit biotin conjugated antibody (Santa Cruz Biotechnology) in PBS for 30 min at 37°C. The sections were then washed again for three times for 5 min in PBS at room temperature. To visualize the protein expression of PKC-⑀ and PKC-␦, each section was incubated in 10 g/ml labeled fluorescein isothiocyanate (Pierce, Rockford, IL) at 37°C for 15 min. Nuclear staining was achieved with 1 mM To-Pro-3 (Molecular Probes, Eugene, OR) at 37°C for 3 min. The protein expression of each section was incubated in 10 g/ml labeled fluorescein isothiocyanate at 37°C for 15 min. Images were obtained at a magnification of 400ϫ using a laser fluorescence imaging system and a confocal microscope (Nikon). A krypton-argon laser was used for excitation at wavelengths of 488 and 633 nm. Emitted fluorescence was determined after long-pass filtering at corresponding wavelengths of 520 and 661 nm for fluorescein isothiocyanate and To-Pro 3, respectively.
Statistical Analysis
Data were analyzed using the following software: pClamp8 (Axon Instruments), Origin 6 (Originlab, Northampton, MA), and StatView version 5.0 (SAS Institute, Cary, NC). Results are reported as mean Ϯ SD. Statistical analysis was performed using the Kruskal-Wallis test with Scheffé methods. Differences were considered significant at P Ͻ 0.05.
Results
Effects of PKC-⑀ on the Modulation of the SarcK ATP Channel by Isoflurane
As previously reported, under whole cell conditions where the intracellular ATP concentration was set nominally at 0.5 mM ATP, isoflurane alone was unable to elicit sarcK ATP channel activity. 26 This is demonstrated in figure 1A. Approximately 25 min of control recordings were obtained to allow for the diffusional exchange of the pipette solution with the intracellular milieu. The subsequent exposure to isoflurane did not result in the activation of an outward current. Pinacidil (20 M) was added to the bath solution at the end of the recording period to confirm the availability of functional sarcK ATP channels.
In contrast, pretreatment with a specific PKC-⑀ agonist peptide PP106 resulted in the opening of the sarcK ATP channel by isoflurane. A representative time-course ex- periment is demonstrated in figure 1B . PP106 (200 nM) was applied in the bath solution for 10 min before exposing the ventricular myocyte to isoflurane. In the presence of isoflurane (0.88 mM), a time-independent outward current was then elicited. The effect of isoflurane was sustained despite washout of the volatile anesthetic. The inhibition of the current by glibenclamide (0.5 M) confirmed it as I KATP . The mean I KATP density in the presence of isoflurane after pretreatment with PP106 was 40.4 Ϯ 18.2 pA/pF (n ϭ 7).
Because the PKC-⑀ agonist peptide seemed to prime the opening of the sarcK ATP channel by isoflurane, whether the isoflurane-activated I KATP amplitude was dependent on the concentration of the peptide was tested. Using the experimental protocol described above, 100 nM PP106 resulted in a markedly smaller I KATP in the presence of isoflurane. The mean isoflurane-activated K ATP current density was 6.5 Ϯ 6.0 pA/pF (n ϭ 7), which was significantly smaller than the one obtained from the pretreatment with the higher concentration of the PKC-⑀ agonist peptide. Therefore, these results showed a concentration-dependent effect of PKC-⑀ translocation on the modulation of the sarcK ATP channel by isoflurane.
To confirm that the observed effects of PP106 were due to the translocation of PKC-⑀, a specific PKC-⑀ translocation inhibitor peptide, PP93 (200 nM), was applied before exposing the myocyte to PP106. The result is depicted in figure 2A . The time-course experiment demonstrates that the inhibitor peptide abolished the effects of the agonist peptide, whereby isoflurane was unable to elicit I KATP . Subsequent activation of I KATP by pinacidil confirmed the functional availability of the sarcK ATP channels. Similar results were obtained in n ϭ 7 cells. In addition, a scrambled peptide of the PKC-⑀ agonist, PP105, was used to further confirm the observed effects of PKC-⑀. As shown in figure 2B , pretreatment with PP105 did not elicit I KATP in the presence of isoflurane. Similar observations were made in n ϭ 7 cells.
Effects of PKC-␦ on the Modulation of the SarcK ATP Channel by Isoflurane
In addition to the PKC-⑀ isozyme, PKC-␦ has also been implicated in the mechanism underlying preconditioning of the myocardium. Therefore, the effect of PKC-␦ on the modulation of the sarcK ATP channel by isoflurane was also investigated. Similar to the experiments described above, a specific translocation activator peptide of PKC-␦, PP114, was used. As depicted in figure 3A , PP114 (200 nM) was applied extracellularly for approximately 10 min before exposure to 0.88 mM isoflurane. As shown in the figure, pretreatment with the PKC-␦ activator did not elicit I KATP in the presence of isoflurane. This was in contrast to the activation of I KATP observed in figure 1B after pretreatment with the PKC-⑀ activator.
In n ϭ 8 cells tested, 6 did not result in the activation of I KATP . However, in the remaining two cells, I KATP activation was observed (data not shown). Due to the activation of I KATP in two of the eight cells, the mean I KATP density was 12.5 Ϯ 22.1 pA/pF, which was significantly different from zero current ( fig. 3B) .
A higher concentration of PP114 was also tested. When cells were pretreated with 400 nM PP114, I KATP was elicited by isoflurane in four out of seven cells. Despite the observation that the higher concentration of PP114 resulted in a relatively more consistent activation of I KATP in the presence of isoflurane, the mean I KATP densities after pretreatment with 200 or 400 nM PP114 were not significantly different ( fig. 3B ). With 400 nM PP114, I KATP density was 5.7 Ϯ 4.1 pA/pF. However, I KATP densities after the pretreatment with either 200 or 400 nM PP114 were significantly less than those recorded after the pretreatment with 200 nM PP106, the PKC-⑀ activator peptide. Furthermore, to confirm that the observed effects were due to the translocation of the PKC-␦ isoform, the effects of a specific PKC-␦ inhibitor peptide, PP101, were determined. Pretreatment with PP101 (200 nM) before the application of the PP114 activator (400 nM) did not elicit I KATP activation by isoflurane in n ϭ 7 cells (data not shown).
The Effect of 5-HD on the modulation of the sarcK ATP channel by PKC-⑀
Recent reports provide strong evidence that the mi-toK ATP channel plays a pivotal role during the initial phases of cardioprotection by IPC and APC. The mi-toK ATP channel is also modulated by PKC. 27 Consequently, the potential role of the mitoK ATP channel in the priming effect of PKC-⑀ on the sarcK ATP channel was investigated. 5-HD (200 M), the putative blocker of the mitoK ATP channel, was added before the pretreatment of the cells with the PKC-⑀ activator PP106 (200 nM) and was subsequently present throughout the course of the experiment. As demonstrated in figure 4A , in the presence of 5-HD, the isoflurane-activated I KATP density of 4.8 Ϯ 2.9 pA/pF (n ϭ 7) after pretreatment with PP106 was markedly smaller than that observed in the absence of 5-HD. Figure 4B summarizes the effects of the PKC-⑀ activator on the isoflurane-activated I KATP in the absence and presence of 5-HD. 
Translocation of PKC-⑀ and PKC-␦
In the patch clamp experiments described above, specific PKC-⑀ and PKC-␦ activators were used to induce the translocation of the isozymes to their respective anchoring proteins localized in the membrane. To assess the endogenous expressions of PKC-⑀ and PKC-␦, immunohistochemical analysis was performed. In these experiments, hearts were obtained from control guinea pigs and those that were previously exposed to 1 MAC isoflurane for 30 min to simulate an anesthetic-preconditioning period. Thoracotomy was performed to extract the heart tissues. For the guinea pigs that underwent APC, thoracotomy was performed after a 30-min recovery period after isoflurane exposure. The results are summarized in figure 5 . After the APC protocol, the translocation of PKC-⑀ was localized to both the mitochondrial and sarcolemmal membranes, although translocation to the nuclei was also likely. In contrast, the translocation of PKC-␦ was localized to the mitochondria but not the sarcolemma after APC. Both isozymes of PKC were detected in the cytosol in the control group.
Discussion
A novel finding from this study is that a specific isozyme, PKC-⑀, primed the sarcK ATP channel to open by isoflurane. The effect of PKC-⑀ on the sarcK ATP channel was concentration dependent. PKC-␦ was significantly less effective in priming the sarcK ATP channel. Although studies have demonstrated that PKC activation by phorbol esters can increase channel activity 28 or prime the channel for activation, 22 isozyme-specific effects on the sarcK ATP channel have not been previously demonstrated. The results from this study demonstrate that the translocation of PKC-⑀ to the sarcolemma would likely result in the anchoring of the isozyme near its substrate and facilitate the modulation of its target protein, e.g., the sarcK ATP channel. The difference in the effectiveness of PKC-⑀ and PKC-␦ to prime the sarcK ATP channel was likely not due to differential expressions of the endogenous isozymes, because both were detected in the cytosol in the control group, as assayed by immunohistochemistry. In addition, the immunohistochemical analysis showed that PKC-⑀ but not PKC-␦ translocated to the sarcolemma in the APC group, which supports the findings from the patch clamp experiments that PKC-⑀, more so than PKC-␦, plays a greater role in the priming of the sarcK ATP channel to isoflurane.
A study by Uecker et al. 20 showed that in rat hearts, PKC-⑀ translocated to the nuclei, sarcolemma, and intercalated disks, whereas PKC-␦ translocated to the nuclei and mitochondria after preconditioning with isoflurane. However, a recent study by Ludwig et al. 29 reported that in rat hearts, isoflurane induced translocation of PKC-⑀ and PKC-␦ to the mitochondrial and sarcolemmal membranes, respectively. Furthermore, in human atrial tissue, preconditioning with sevoflurane resulted in the translocation of PKC-⑀ to the mitochondria, nuclei, and intercalated disks and PKC-␦ to the sarcolemma. 30 Our results from the guinea pig hearts demonstrated that isoflurane translocated PKC-⑀ to the sarcolemma and mitochondria and PKC-␦ was translocated to the mitochondria.
Currently, it is evident that translocations of PKC are pivotal steps involved in cardioprotection by preconditioning. 31 The PKC family contains 12 distinct isozymes, which are classified into three subfamilies: conventional (␣, ␤ 1 , ␤ 2 , ␥), novel (␦, ⑀, , ), and atypical (, , , ). Among these, PKC-␦ and PKC-⑀ seem to play critical roles in the signaling cascade underlying preconditioning. 19, 20, 32 Because the types and levels of PKC isozyme expression vary among species, 31 reports on translo- cated PKC isozymes in preconditioning have been inconsistent. [32] [33] [34] [35] Furthermore, the different types of preconditioning, pharmacologic 35, 36 and ischemic, 33, 35, 36 may contribute to differential roles for the various PKC isozymes. For example, studies on simulated ischemia in isolated myocytes confirm a pivotal role for PKC-⑀ in ischemic preconditioning whereby a selective peptide inhibitor of the PKC-⑀ isozyme, ⑀V1-7, abolished preconditioning. 37 Activation of PKC-⑀ that leads to cardioprotection has also been shown to couple to recruitment of PKC-⑀-associated proteins. 17, 38 In isolated perfused rat hearts, inhibition of PKC-␦ prevented reperfusion injury and activation of PKC-⑀ mimicked ischemic preconditioning. 18 In opioid-induced preconditioning, activation of PKC-␦ was shown to be essential. 39 In contrast, PKC-␦ was found to be detrimental, whereas PKC-⑀ activation was required for ethanol-induced cardioprotection. 36 For volatile anesthetic-induced preconditioning, the translocation of specific PKC isozymes may be dependent on the animal model and the choice of anesthetic agent. Inhibition of PKC-␦ by rottlerin, a specific blocker, abolished APC in an isolated rat heart model of isoflurane-induced preconditioning. 20 In this model, IPC was also inhibited by rottlerin. However, in isolated guinea pig hearts, a PKC-⑀ inhibitor peptide abolished sevoflurane-induced preconditioning. In contrast, a PKC-␦ inhibitor peptide had no effect. 19 The importance of the mitoK ATP channel in APC and IPC has been demonstrated in numerous studies, but the role of the sarcK ATP channel has not been clearly defined. A recent study showed that the efficacy of IPC was significantly attenuated in knockout mice deficient in the gene encoding the pore-forming region of the sarcK ATP channel, Kir6.2. 14 Functional mitoK ATP channel activity was assessed by monitoring flavoprotein fluorescence in the knockout mice. Therefore, despite functional mi-toK ATP channels, the absence of the sarcK ATP channel diminished the cardioprotective effects of IPC. These results were also supported by a study using transgenic mice expressing a mutant Kir6.2 with diminished ATP sensitivity. 40 Hearts from the transgenics did not exhibit postischemic recovery after IPC. A more recent study using Kir6.2-knockout mice demonstrated that diazoxide did not improve functional recovery in these mice. 41 Moreover, the cardioprotective effects of diazoxide on the wild-type mice were abolished by HMR 1098, suggesting that the sarcK ATP channels were involved. 41 Other studies have demonstrated that the opening of the mitoK ATP more so than the sarcK ATP channel plays a prominent role during preconditioning of isolated human right atria by sevoflurane. 42 However, in that study, block of the sarcK ATP channel by a putative blocker, HMR1098, significantly attenuated the recovery force at the end of a 60-min reoxygenation period. 42 In some cases, preconditioning may require both mi-toK ATP and sarcK ATP channels. The protective effects of desflurane were found to involve both the mitoK ATP and sarcK ATP channels because either 5-HD or HMR1098 abolished the preconditioning effects of the anesthetic in anesthetized dogs. 13 These channels may also have separate, distinct roles in preconditioning. During adenosine-enhanced ischemic preconditioning, the mi-toK ATP channel reduced infarct size during ischemia, whereas the sarcK ATP channel modulated functional recovery during ischemia and reperfusion. 43 Similar roles for the K ATP channels were reported in an hypoxia/ reoxygenation model using isolated myocytes. 21 In a recent study on the delayed-protection by isoflurane, 5-HD and HMR 1098 partially attenuated the anestheticinduced cardioprotective effects. 44 However, a combination of both 5-HD and HMR 1098 abolished the isoflurane-induced cardioprotection, suggesting that both mitoK ATP and sarcK ATP channels are involved in the delayed protection by isoflurane. 44 The results obtained in our study support the hypothesis that both the mitoK ATP and sarcK ATP channels are involved in APC in the guinea pig model. The modulation of the sarcK ATP channel may occur subsequent to changes in the signaling cascade triggered by mitoK ATP channel opening. In isoflurane-induced preconditioning, the opening of the mitoK ATP channel was found to trigger the cardioprotective signaling cascade by generating reactive oxygen species. 45 Downstream of the generated reactive oxygen species, PKC activation, in particular PKC-⑀, has been shown to occur in sevoflurane-induced preconditioning. 19 Based on our results, the priming of the sarcK ATP channel by PKC-⑀, following the opening of the mitoK ATP channel, would sensitize this channel to isoflurane. Other intracellular pathways linked to cardioprotection have also been shown to modulate the sarcK ATP channel. For example, the protein tyrosine kinase and phosphatase signaling pathway can modulate the sensitivity of the sarcK ATP channel to isoflurane. 46 Therefore, activation of the mitoK ATP channel, particularly during the initial phase of preconditioning, seems to be a critical step in triggering the signaling cascade that leads to cardioprotection. Although the role of the sarcK ATP channel has not been defined, it may contribute as an effector, whereby the channel is modulated by the signaling components activated by the opening of the mitoK ATP channel. In particular, as discussed above, the opening of the sarcKATP channel during reperfusion after a prolonged ischemic period may facilitate functional recovery of the myocardium. One recent study demonstrated that opening of the sarcK ATP channel can modulate the Na-Ca exchanger, resulting in a decreased influx of Ca 2ϩ ions and attenuation of Ca 2ϩ overload. 47 An intriguing result from our study was the attenuation of the priming effects of PKC-⑀ on the sarcK ATP channel by 5-HD. This implied that the mitoK ATP channels might mediate the priming of the sarcK ATP channel. However, the contribution of the mitoK ATP channel is unclear.
Under the whole cell recording conditions, the intracellular ATP concentration is set by the solution in the recording pipette, which in this case was nominally 0.5 mM ATP. Consequently, cross-talk between the mitochondria and sarcK ATP channel, whereby ATP consumption by uncoupled mitochondria leads to opening of the sarcK ATP channel, is unlikely to have occurred. One possibility, though, is that PKC-⑀ may lead to mitoK ATP channel activation, 27 resulting in the generation of reactive oxygen species that was sufficient enough to prime the sarcK ATP channel downstream. Another possibility is the inhibition of the sarcK ATP channel by 5-HD. 48 However, in control experiments, 5-HD did not affect I KATP elicited by pinacidil in our studies (data not shown). Yet another possibility is that the effects of 5-HD may be due to its mitoK ATP channel-independent targets. 5-HD has recently been demonstrated to serve as a substrate for acyl-CoA (coenzyme A) synthetase, resulting in 5-hydroxydecanoyl-CoA, which then can act on other intracellular targets. 49 Long-chain acyl-CoA esters have been shown to increase sarcK ATP channel activity by reducing the sensitivity of the channel to ATP. 49 This scenario is unlikely based on our observations because in this case, 5-HD would have increased channel activity. Nevertheless, the observed effect of 5-HD suggests a possible coupling between the mitochondria and the sarcK ATP channel. Further experiments would be needed to elucidate the mechanism underlying the 5-HD effect on the priming of the sarcK ATP channel by PKC-⑀.
We cannot exclude the possibility that a brief hypoxic condition induced during thoracotomy before extraction of cardiac tissues resulted in the translocation of specific PKC isozymes. In addition, the cell isolation procedure using collagenase may also activate PKC isozymes. However, despite these possibilities, the immunohistochemical data suggest that "additional" translocation of the PKC-⑀ isozyme to the mitochondria and sarcolemma occurred after the APC protocol. Furthermore, translocation of PKC-␦ to the mitochondria was also detected after APC.
In summary, the results from this study show a priming effect of PKC-⑀ on the sarcK ATP channel. After pretreatment with a specific PKC-⑀ translocation activator, isoflurane elicited the opening of the sarcK ATP channel. The ability of PKC-␦ to prime the sarcK ATP channel was significantly less than that of PKC-⑀. Our results suggest that the modulation of the sarcK ATP channel by PKC-⑀ may occur downstream of mitoK ATP channel activation.
